The Expanding Market for Respiratory Infection Therapy: Focus on Non-Cystic Fibrosis Bronchiectasis
Respiratory infections are a leading cause of morbidity and mortality worldwide, and for patients with non-cystic fibrosis bronchiectasis, they represent a recurrent and serious threat. Effective respiratory infection therapy is essential for breaking the cycle of infection and inflammation that characterizes this disease. The market for respiratory infection therapy is growing,...
0 Comments 0 Shares 109 Views 0 Reviews